Company
a world leader in allergy diagnosis and specific allergen immunotherapy
Every investor coverage indicates participated in a round ALK-Abello A/S raised.
Companies ALK-Abello A/S acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Carsten Hellmann | President & CEO (former) | Brandon Capital, Brandon Capital portfolio |
Stories naming ALK-Abello A/S. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Aravax, developer of the peanut allergy immunotherapy PVX108, adds former ALK-Abello chief Carsten Hellmann and ex-Aimmune commercial head Andrew Oxtoby to its board ahead of Phase 3.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com